Following in the footsteps of Gilead Sciences, Merck & Co. | Following in the footsteps of Gilead, Merck has signed voluntary licensing agreements to enable access to its investigational HIV PrEP pill alimatravir ahead of any regulatory submissions.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
A combination of Merck’s islatravir and Gilead’s lenacapavir has
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has what…
Merck is striking licensing deals for its experimental HIV prevention pill in hope of getting wide-scale production started…
Novo Nordisk sues Eli Lilly over misleading ads; Merck licenses alimatravir; AbbVie/Genmab clarify Epkinly trial; J&J touts…
Seven generic drug manufacturers sign royalty-free agreements to produce experimental once-monthly HIV pill
Gilead-Merck detail Phase 3 HIV data, Dimension Capital closes $800M fund, WuXi AppTec fights DoD blacklist bid, and more.
